CBIOHIGH SIGNALRISK10-K

CBIO underwent a complete corporate transformation including jurisdiction change from Delaware to Cayman Islands and experienced a near-total collapse in revenue.

The simultaneous jurisdiction change to Cayman Islands and dramatic reduction in outstanding shares from 64.5 million to 27.6 million suggests a major corporate restructuring or reorganization event. The language changes indicate this may involve a fundamental business model shift or significant corporate action that investors should carefully evaluate for impact on their holdings.

Comparing 2026-02-26 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

The company experienced a catastrophic revenue decline from $20.1M to just $19K, representing a near-complete elimination of business activity. This dramatic financial deterioration, combined with the corporate restructuring evidenced by the jurisdiction change and share count reduction, signals either a major business pivot, distressed situation, or fundamental transformation of the company's operations.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-99.9%
$20.1M→$19K

Revenue declined 99.9% — significant demand weakness or market share loss warrants investigation.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-13
ADDED
(Exact name of registrant as specified in its charter) ________________________________ Cayman Islands 06-1686563 (State or other jurisdiction of incorporation or organization) (I.R.S.
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act.
The number of the Registrant s Ordinary Shares outstanding as of February 23, 2026 was 27,556,767 .
Market for Registrant s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 103 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 105 Item 7A .
+7 more — sign up free →
REMOVED
(Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) P.O.
See definitions of large accelerated filer, accelerated filer , smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
At February 7, 2025, 64,513,862 shares of GlycoMimetics, Inc.
s Common Stock, $0.001 par value per share, were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations, but are also contained elsewhere in this Annual Report.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →